Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB cut its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 9.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 85,300 shares of the company’s stock after selling 9,400 shares during the quarter. Handelsbanken Fonder AB owned 0.30% of Krystal Biotech worth $13,363,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. State Street Corp lifted its holdings in Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after buying an additional 119,936 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Krystal Biotech by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after purchasing an additional 11,411 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Krystal Biotech by 34.2% in the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after purchasing an additional 62,178 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Krystal Biotech by 9.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company’s stock valued at $43,727,000 after purchasing an additional 19,777 shares in the last quarter. Finally, Braidwell LP raised its holdings in shares of Krystal Biotech by 57.4% in the 3rd quarter. Braidwell LP now owns 168,691 shares of the company’s stock valued at $30,707,000 after purchasing an additional 61,512 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $187.86 on Friday. Krystal Biotech, Inc. has a 1 year low of $107.50 and a 1 year high of $219.34. The firm has a 50 day moving average price of $157.37 and a 200 day moving average price of $175.23. The company has a market cap of $5.40 billion, a price-to-earnings ratio of 62.83 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. During the same period in the previous year, the firm earned $0.30 earnings per share. Krystal Biotech’s revenue was up 116.4% compared to the same quarter last year. Sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. This represents a 1.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 14.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on KRYS shares. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a report on Thursday. Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday. Chardan Capital raised their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday. Finally, HC Wainwright restated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech currently has an average rating of “Buy” and a consensus price target of $210.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).